XNAS · KPRX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Kiora Pharmaceuticals, Inc. Common Stock

Kiora Pharmaceuticals, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$2.63
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is KPRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Kiora Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
13
Country
US

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.63
Last session
Day high
$2.63
Last session
Day low
$2.63
Last session
Previous close
$2.63
52W high
$2.74
-4.01% from high
52W low
$2.43
65% of range
Market cap
$11.7M
EPS
$-1.6300
Shares out
4.4M
VWAP
$2.63
Last session
Price history computed in-house
1W
+3.54%
SMA 50 $2.58 · above
SMA 200 $2.58 · above
52W position 65%
Veridion warehouse edge

Warehouse intelligence for KPRX.

Veridion Score
85
0: 941: 472: 713: 704: 795: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

KPRX insider activity

Kiora Pharmaceuticals, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for KPRX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

KPRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KPRX in this window.
Lobbying spend

KPRX lobbying filings, year to date.

Registered lobbying filings matched to Kiora Pharmaceuticals, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KPRX in this window.
Latest news · KPRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for KPRX.
Options
Sovereign unlock shows live options positioning for KPRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.